



Innovative back microsurgery

Press release

VEXIM postpones its private placement

Toulouse, June 5th 2013 - VEXIM (FR0011072602 – ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, has today decided to postpone the private placement announced on June 3rd, as the expected conditions for its execution were not met. VEXIM was considering this private placement as a means to finance the acceleration of its clinical and commercial development.

Vincent Gardès, CEO of VEXIM, states: *“In view of the excellent operational and commercial performances recorded in 2012 (with sales doubling), reaffirmed by the buoyant growth in our activity over the 1st quarter of 2013 (+113%), as well as our international growth prospects thanks to the talks currently taking place with potential partners, the Board of Directors has decided to protect the VEXIM’s stock rather than undertake an operation deemed too dilutive. We will pursue our winning growth momentum by building on the outstanding success of the SpineJack® implant, over 5,000 of which have been implanted so far in Europe by spine surgeons. Our long-term objective to become the European leader in innovative back microsurgery remains unaffected.”*

The Company will examine any opportunities to finance its growth in order to create value for its shareholders, whether with new investors or thanks to the steadfast support of its historic shareholder, Truffle Capital.

Philippe Pouletty, CEO of Truffle Capital, VEXIM’s main shareholder, concludes: *“Given the company’s operational and commercial solidity and its international growth prospects, we are considering providing VEXIM with, if necessary, financing solutions in the form of convertible bonds or any other form that would create value for all shareholders.”*

About Vexim, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital¹ and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 45 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Turkey, Argentina, India and in the following countries where the product is currently being registered: Mexico, Brazil, Taiwan, Colombia, Venezuela, Chile, Ecuador and Peru. Vexim has been listed on NYSE Alternext Paris since May 3rd 2012.

For further information, please go to www.vexim.com

SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.com and www.fcpi.fr.

Contacts

VEXIM

Vincent Gardès

CEO

Tel: +33 5 61 48 48 38

investisseur@vexim.com

NewCap.

Financial Communications
and Investor Relations

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol

caroline@alizerp.com

Tel: +33 6 64 18 99 59

Christian Berg

christian@alizerp.com

Tel: +33 1 42 68 86 41



- **Name:** Vexim
- **ISIN Code:** FR0011072602
- **Ticker:** ALVXM

Disclaimer

This announcement does not, and shall not, in any circumstances, constitute a public offering nor an offer to subscribe nor an invitation to the public in any jurisdiction in connection with any offer.

This press release does not constitute or form part of an offer or solicitation of an offer to subscribe for securities in France. The securities referred to herein may not be and will not be offered or sold to the public in France except to qualified investors and/or to a restricted circle of investors, acting for their own account, as defined in, and in accordance with Articles L. 411-2 II, D. 411-1 and D. 411-4 of the French Monetary and Financial Code.

With respect to the member states of the European Economic Area, other than France, which have implemented the Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003, as amended, in particular by Directive 2010/73/EC of the European Parliament and of the Council of November 24, 2010 (the "Prospectus Directive"), no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member state. As a result, the securities may not and will not be offered in any relevant member state except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member state, or under any other circumstances which do not require the publication by VEXIM of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member state.

This announcement and the information contained herein do not constitute an offer or solicitation of an offer to subscribe for securities in the United States or any other jurisdiction where such offers or solicitations may be subject to restrictions. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The shares of VEXIM have not been and will not be registered under the U.S. Securities Act and VEXIM does not intend to register securities or conduct a public offering in the United States.

In the United Kingdom, this announcement is directed only at persons that are "qualified investors" within the meaning of the Prospectus Directive and that also (i) are "investment professionals" (persons having a professional experience in investment) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). In the United Kingdom, this announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

The distribution of this announcement in certain countries may be subject to specific regulations. The persons in possession of this announcement shall then get knowledge of any local restrictions and shall comply with these restrictions.

This information does not fall under the responsibility the brokerage firm Invest Securities and Societe Generale Corporate & Investment Banking and have not been independently verified by the brokerage firm Invest Securities and Societe Generale Corporate & Investment Banking.

No copy of this announcement has been or should be distributed or sent to the United States, Canada, Japan or Australia.